Contextualizing the Clinical Journey of Belantamab Mafodotin as a BCMA Targeting ADC in Treatment of Relapsed or Refractory Multiple Myeloma

Time: 4:30 pm
day: Day Two PM


  • Exploring preclinical evidence of Belantamab Mafodotin’s underlying mechanism of action in support of monotherapy development and rationale for synergy in combination
  • Breaking down the clinical journey from statistically negative DREAMM-3 monotherapy readout to positive combination therapy data with DREAMM-7 and DREAMM-8
  • Explaining the regulatory vs. clinical journey to better understand strength of evidence of Belantamab Mafodotin as a monotherapy and in combinations